Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations and Cytori’s Medical Affairs activities.
“Dr. Kesten is a seasoned physician executive with more than 30 years of experience in medicine,” said Dr. Hedrick. “This experience includes involvement in high profile clinical trials, leading medical affairs activities, and navigating complex reimbursement environments. Dr. Kesten’s contributions will further strengthen our clinical program, starting with our cardiovascular business and extending to future therapeutic areas.”
Most recently Dr. Kesten served as Vice President and Chief Medical Officer at Uptake Medical, where he oversaw the completion of the VAPOR trial and had medical responsibility for the application that led to the CE Mark approval of Uptake Medical’s device, InterVapor ®. He previously served for more than ten years at Boehringer Ingelheim, most recently as the Vice President in Medicine for Marketed Products for respiratory disease. During his tenure, Dr. Kesten was responsible for the development and execution of multiple large-scale clinical trials and took the medical lead in the global registration, branding and reimbursement of the drug Spiriva ®, a $3 billion worldwide product for chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three years and is experienced in European regulatory affairs and reimbursement strategies.
In addition, Dr. Kesten held the position of medical director of the Rush Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St. Luke’s Medical Center in Chicago. Dr. Kesten received his medical degree and specialty training in internal medicine and pulmonary medicine at the University of Toronto and has more than 160 peer-reviewed publications.About Cytori Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution System product family. www.cytori.com
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts